AstraZeneca and the University of Oxford got the go-ahead to restart their US coronavirus vaccine trials.
The late-stage trial was stopped due to a possible adverse reaction in one of the participants.
On September 6 AstraZeneca reported a "suspected serious adverse reaction".
According to Business Insider, the reaction occurred in a UK-based participant.
The UK resumed clinical trials for AstraZeneca and the University of Oxford vaccines in September.
